tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Xeris Pharmaceuticals (XERS) and Athersys (ATHX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aprea Therapeutics (APREResearch Report), Xeris Pharmaceuticals (XERSResearch Report) and Athersys (ATHXResearch Report).

Aprea Therapeutics (APRE)

In a report released today, Esther Hong from Berenberg Bank maintained a Hold rating on Aprea Therapeutics, with a price target of $4.00. The company’s shares closed last Tuesday at $1.74, close to its 52-week low of $1.46.

According to TipRanks.com, Hong is ranked 0 out of 5 stars with an average return of -23.7% and a 18.4% success rate. Hong covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Aldeyra Therapeutics, and Axsome Therapeutics.

Currently, the analyst consensus on Aprea Therapeutics is a Hold with an average price target of $4.00.

See today’s best-performing stocks on TipRanks >>

Xeris Pharmaceuticals (XERS)

In a report released today, Vamil Divan from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals, with a price target of $6.00. The company’s shares closed last Tuesday at $2.67.

According to TipRanks.com, Divan is a 1-star analyst with an average return of -2.7% and a 47.0% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, ACADIA Pharmaceuticals, and Revance Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xeris Pharmaceuticals with a $6.00 average price target, a 134.4% upside from current levels. In a report issued on March 10, Leerink Partners also reiterated a Buy rating on the stock with a $6.00 price target.

Athersys (ATHX)

Needham analyst Gil Blum maintained a Buy rating on Athersys today and set a price target of $5.00. The company’s shares closed last Tuesday at $0.69, close to its 52-week low of $0.67.

According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -33.8% and a 12.4% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Aeglea Biotherapeutics.

Athersys has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on APRE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed